Leerink Partners analyst Mani Foroohar maintained a Buy rating on RegenXBio (RGNX – Research Report) on February 20 and set a price target of ...

In a report released on February 19, Mike Kratky from Leerink Partners reiterated a Buy rating on Penumbra (PEN – Research Report), with a ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform to Outperform. Analyst Price Forecast Suggests 28.91% Downside As of ...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief ...

Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...

LUND, SE / ACCESS Newswire / February 19, 2025 /Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargia's management will participate in one-on-one ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Outperform recommendation. As of January 29, 2025, the average one-year price ...